This review looks at why some patients with advanced epithelial ovarian cancer do not respond well to PARP inhibitors. The researchers identified several ways the cancer cells adapt to the treatment. These include changes in DNA repair pathways, the way cells handle damage, and the way the tumor environment changes over time.
One major reason for treatment failure is the diversity within a single tumor. This variety allows some cancer cells to survive and grow even when the medicine is present. Other factors include the cancer cells changing their genetic makeup or finding ways to pump the medication out of their systems.
Because this is a narrative review, it summarizes existing knowledge rather than reporting on a new clinical trial. The findings are intended to help doctors understand why resistance happens. This knowledge may help them choose better combinations of drugs or use more frequent testing to monitor how the cancer is changing.
Common questions
Why does ovarian cancer sometimes stop responding to PARP inhibitors?
Cancer cells can develop resistance through several mechanisms. These include changes in how they repair DNA, mutations that restore certain pathways, and the ability to pump drugs out of the cell. The tumor environment and the diversity of cells within the tumor also play a role in making treatment less effective over time.
What factors contribute to the failure of these treatments?
Treatment failure can be caused by intratumoral heterogeneity and the remodeling of the tumor microenvironment. These factors can lead to the selection of cancer cells that are specifically resistant to the medication. Understanding these dynamics helps researchers look for better ways to manage advanced epithelial ovarian cancer.
How can doctors monitor for these changes in treatment?
The review suggests that dynamic molecular profiling can help track how a cancer is changing. Methods such as ctDNA and HRP assays are mentioned as ways to monitor the tumor's response and identify when it is developing resistance to current therapies.
